NCT04310098 · RECRUITING
CADASIL Registry Study
This is a registry study — not a drug trial — tracking people with CADASIL, a rare inherited condition that damages small blood vessels in the brain and causes strokes and dementia. Researchers are following patients over time to understand how the disease progresses and how to manage it better. There is no experimental treatment involved. Because the phase is unspecified, this is an observational study, not a test of whether something works.
You may qualify if
- Sign informed consent.
- Age>18
- Clinical diagnosis of patients with CADASIL,and confirmed by genetic test or skin biopsy
- Asymptomatic NOTCH3 mutation carriers
- Relatives of CADASIL patients or carriers
- Unrelated healthy controls
You're excluded if
- Unable to cooperate with inspectors
- Serious systemic illness, such as heart, liver, kidney disease or major mental illness
- Contraindications for imaging examination
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2023-09-28